Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Bristol-Myers

Here's how these two big drugmakers stack up against each other in several key categories.

Better Buy: Amgen vs. Bristol Myers Squibb

Alexion Pharma

BioMarin Pharmaceutical

Insmed

Regeneron Pharmaceuticals

United Therapeutics

Vertex Pharmaceuticals

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

7 Large Biotechs Expected to Outperform This Earnings Season

Johnson & Johnson

Pfizer

For less than $500 you can get these successful drugmakers to send you a growing share of their bottom line.

Got $500? 3 Big Pharma Stocks You Can Buy Now That Pay Dividends

Ameriprise Financial

Blackrock Inc

Hershey

T. Rowe Price Group

Last month, I defined 15 high-quality "DARPA" stocks that provide both dividends And reasonable price appreciation.

Tracking The DARPA Portfolio: Dividends And Reasonable Price Appreciation Stocks One Month In

Cytokinetics

Amgen Inc. (NASDAQ:AMGN) and its partner, Cytokinetics Inc. (NASDAQ:CYTK), took a punch to the gut last week when the heart drug they were collaborating on failed to meet expectations. Thousand Oaks, California-based Amgen saw its share price drop about 8% to under $237, while Cytokinetics nearly halved its market value—to just more than $1 billion-- when the South San Francisco biopharma's stock plunged to $15.26.

Amgen, Cytokinetcs Shares Punished on Disappointing Test Results

Shares of Amgen Inc. (NASDAQ:AMGN) sold off last week as the company received some bad news regarding a trial for one of the drugs it is working on with other companies.

Amgen is Now Fairly Valued

Biogen

Gilead Sciences

Moderna

The short interest data are out for September 30, the most recent settlement date.

Short Sellers Need to Find a Clue on Major Biotechs

Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.

Amgen Down on Unsatisfactory Heart Failure Drug Study Results

Neurocrine Biosciences

With earnings season about to kick off, investors are being forced into a different sort of earnings season.

4 Very Profitable Biotech Stocks Expected to Soar Into 2021

Shares of Amgen Inc. dropped 1.8% in morning trading Friday, enough to pace the Dow Jones Industrial Average's decliners, after Truist analyst Robyn Karnauskas downgraded the biotechnology company, citing disappointing trial results of its treatment for heart failure.

Amgen's stock paces the Dow's decliners after analyst downgrade in wake of disappointing trial results

Amgen and Cytokinetics disappointed with key Phase 3, final-stage trial results for a heart treatment that aims to reduce cardiovascular death; sending CYTK crashing and AMGN down hard. The post Amgen, Cytokinetics Partnership Disappoints With Data On Heart Treatment appeared first on Investor's Business Daily.

Amgen, Cytokinetics Partnership Disappoints With Data On Heart Treatment

THOUSAND OAKS, Calif., Oct. 5, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients with KRAS G12C-mutant advanced non-small cell lung cancer...

Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer

CAMBRIDGE, England--(BUSINESS WIRE)--Amgen today announced a new partnership with two NHS organisations, the North West Coast Innovation Agency and Imperial College Health Partners. This collaboration will help tackle the ‘silent killer’ of high cholesterol across the North West Coast of England – an area heavily impacted by heart attacks, strokes, and premature deaths due to cardiovascular disease (CVD). ‘Control Cholesterol: Collaborating to Reduce Risk’ is an innovative two-year programme ad

Amgen Announces Collaboration With Two NHS Organisations to Help Improve Cholesterol Management for People at High Risk of a Heart Attack or Stroke

Teladoc

Target

These healthcare and retail giants have proven their resilience during a rough-and-tumble year.

Market Crash 2.0: 3 Stocks to Save Your Portfolio

THOUSAND OAKS, Calif., Oct. 3, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results reinforcing the long-term safety and efficacy profile of Aimovig® (erenumab-aooe) in patients with episodic migraine (EM) are being presented at the Migraine Trust Virtual Symposium....

Amgen Announces Five-Year Data That Reinforce The Safety And Efficacy Profile Of Aimovig® (erenumab-aooe) In Adult Patients With Episodic Migraine

Mallinckrodt PLC

Novartis

A House committee has issued detailed reports about some of their drug price increases.

Congressional Committee Accuses Amgen and Peers of Hiking Drug Prices to Meet "Aggressive" Revenue Targets

Our indicative theme on Covid-19 Treatment Stocks is up 13% this year, compared to the 4% gain for the S&P 500. While anti-viral therapeutics are quite complex to develop, companies have largely been adapting existing therapies for Covid treatments while also developing new treatment options.

Gilead, Regeneron, Amgen: Covid Treatment Stocks Still Worth Looking At As Vaccine Nears?

These big biotechs are both moving into new areas. Which is most likely to move the needle for investors?

Better Buy: Gilead Sciences vs. Amgen

The company has had some challenges.  But when looking at the long-term, Amgen stock looks like a good play.

3 Reasons To Be Bullish On Biotech Giant Amgen

AmerisourceBergen

Extra Space Storage

Group 1 Automotive

Stocks include a new addition to the gurus' list of good companies

5 Buffett-Munger Stocks With High Dividend Yields

The short interest data are out for September 15, the most recent settlement date.

Biotech Short Sellers Hike Their Bets

In 2020 investors have been forced to dial down expectations in biotech if their business ambitions are not tied to COVID-19.

Why Amgen Is Called to Outperform Large-Cap Biotechs

BioNTech SE

Sanofi

Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.

Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch

Prudential Financial

Snap-on

Texas Instruments

The core of a dividend portfolio should be made of all weather dividend stocks.

The 5 Undervalued Blue Chip High Dividend Growth Stocks You Need To Buy Now

THOUSAND OAKS, Calif., Sept. 20, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that updated data from the full Phase 1 cohort of the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 129 patients across multiple advanced solid tumors, were...

News for Amgen Stock (AMGN)